Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Lower dose of Pfizer,...

    Lower dose of Pfizer, Eli Lilly blockbuster painkiller tanezumab misses target in late stage study

    Farhat NasimWritten by Farhat Nasim Published On 2019-04-20T10:00:45+05:30  |  Updated On 16 Aug 2021 12:11 PM IST

    The drug, tanezumab, belongs to a new category of pain medications that target nerve growth factor, a protein involved in the growth of nerve cells, and has been touted as a potential blockbuster.


    U.S: A lower dose of non-opioid painkiller developed by Pfizer Inc and Eli Lilly and Co failed to meet main goals in a late-stage study in patients with moderate-to-severe osteoarthritis of the hip or knee, the companies said on Thursday.


    The drug, tanezumab, belongs to a new category of pain medications that target nerve growth factor, a protein involved in the growth of nerve cells, and has been touted as a potential blockbuster.


    Read Also: Pfizer, GSK consumer healthcare venture to focus on China, US market


    The study tested the treatment in two doses, 2.5 mg and 5 mg, comparing the long-term joint safety and effectiveness at the end of 16 weeks with painkillers that are normally prescribed to patients.


    The higher dose of the treatment met two of the three main goals, in which it reduced pain and improved physical function.


    Read Also: Pfizer wins USFDA approval for IBRANCE to treat men with Metastatic Breast Cancer


    There were 10 deaths in the study, of which nine occurred in a group of patients who were given tanezumab. None were considered treatment-related, the companies said.


    Share of Pfizer Inc fell 1.2 per cent at $38.90 in extended trading, while shares of Eli Lilly were marginally down.


    Read Also: Eli Lilly offers generic version of insulin Humalog at half price

    drug tanezumabEli Lillylower dosenon opioid painkillerOsteoarthritispain medicinespainkillerpainkillersPfizerpharmapharma newsShare of Pfizershares of Eli Lillytanezumabtreatment
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok